

TAJIKISTAN

STRATEGIC FOCUS

The partnership between the U.S. Centers for Disease Control and Prevention (CDC) and the Government of Tajikistan began in 1995 to strengthen the country's capacity to detect, prevent, and respond to public health threats. In 2010, CDC began implementing activities supported through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR).

To help Tajikistan achieve HIV epidemic control, CDC supports the Ministry of Health's Republican AIDS Center (RAC) and Republican Narcology Center (RNC) to implement interventions and activities in the following areas: HIV surveillance; prevention, including medication assisted therapy (MAT) for injecting drug users; HIV counseling and testing; HIV care and treatment; and HIV laboratory strengthening.

CDC works to improve the quality and availability of HIV prevention and treatment services for key populations (KPs) and people living with HIV/AIDS (PLHIV); strengthening public health system capacities to implement HIV surveillance, prevention, care, and treatment programs.

CDC supports scaling-up effective HIV prevention services for the most at-risk population, especially KP groups who are disproportionately affected by HIV.

KEY ACTIVITIES AND ACCOMPLISHMENTS

- In 2021, CDC helped the government implement targeted evidence-based HIV testing strategies, including index testing.
- Ninety-four percent of new HIV cases found with CDC's assistance initiated antiretroviral therapy (ART) and 84 percent of them started ART within 7 days of diagnosis. The median time from diagnosis to ART initiation has reduced from 12 to 5 days (Tajikistan Electronic HIV Case Management System (EHCMS), 2022).
- In 2021, CDC supported 47 facilities in three regions in providing ART for 5,313 PLHIV. In 2021, 587 HIV-positive patients started ART in CDC-supported areas for the first time, which contributed to an 11 percent increase overall in patients on ART in those areas (PEPFAR Monitoring, Evaluation, & Reporting, 2022).
- By the end of 2021, CDC technical assistance increased viral load suppression prevalence to 94 percent in three of the highest HIV burden areas in Tajikistan (PEPFAR Monitoring, Evaluation, & Reporting, 2022).
- As of December 2021, nearly all HIV/AIDS centers are reporting on 100 percent of key indicators through the national EHCMS developed by CDC. This system allows for collection and analysis of patient- and summary-level data for improved clinical and program management (Tajikistan EHCMS, 2022).
- CDC continues to work with the RNC to provide comprehensive MAT services to people who inject drugs in three MAT clinics. These activities include dispensing of Opioid Substitution Therapy, HIV testing, integrated care for patients who are positive for HIV, viral hepatitis, and TB, as well as providing psychosocial support.
- CDC supports international external quality assessment and proficiency testing for serology and viral load testing in six HIV laboratories.
- CDC supports the RAC to revise national treatment guidelines; quantify a sufficient supply of quality antiretroviral drugs to implement transition to TLD, a fixed-dose combination HIV drug regimen (tenofovir disoproxil 300mg/lamivudine 300mg/dolutegravir 50mg); and scale-up multi-month ARTs dispensation (MMD). By the end of 2021, approximately 70 percent of ART patients had transitioned to TLD and approximately 70 percent were receiving MMD.
- CDC is supporting the implementation of bio-behavioral population surveys among groups at increased risk for HIV. These surveys will provide critical information on the burden and risk of HIV, access to services, and risk-behaviors among men who have sex with men, people who inject drugs, and female sex workers.

Key Country Leadership

President:
Emomali Rahmon

Minister of Health:
Abdullozoda Jamoliddin

U.S. Ambassador:
John M. Pommersheim

CDC/DGHT Director:
Patrick Nadol

Country Quick Facts
(worldbank.org/en/where-we-work)

Per Capita GNI:
\$1,150 (2021)

Population (millions):
9.75 (2021)

Under 5 Mortality:
32.3/1,000 live births (2020)

Life Expectancy:
71 years (2020)

Global HIV/AIDS Epidemic
(aidsinfo.unaids.org)

Estimated HIV Prevalence
(Ages 15-49): 0.2% (2021)

Estimated AIDS Deaths
(Age ≥15): <200 (2021)

Estimated Orphans Due to
AIDS: 3,600 (2021)

Reported Number Receiving
Antiretroviral Therapy (ART)
(Age ≥15): 7,897 (2021)

**Global Tuberculosis
(TB) Epidemic**
(who.int/tb/country/data/profiles/en)

Estimated TB Incidence:
84/100,000 population (2020)

TB Patients with Known HIV
Status who are HIV-Positive:
2.9% (2020)

TB Treatment Success Rate:
91% (2019)

DGHT Country Staff: 4
Locally Employed Staff: 4

Our success is built on the backbone of science and strong partnerships.

September 2022 | The CDC Division of Global HIV & TB activities are implemented as part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); non-HIV related TB activities are supported by non-PEPFAR funding

